NEXGEL Hosts Investor Update Call on September 24, 2026
News related to:NEXGEL, Inc · 1 min read
LANGHORNE, Pa., Sept. 23, 2026 /CourierPR/ -- NEXGEL, Inc., a company focused on patient-centric medical technology sales and marketing, is set to host an investor update call on September 24, 2026, at 4:15 p.m. Eastern Time. The call will provide investors with an update on the company's operational progress, commercialization initiatives, and other corporate matters.
Interested parties can join the live call by dialing 1-833-309-3473 (U.S. Toll Free) or 1-785-838-9251 (International) and entering the conference ID: NEXGEL. A replay of the call will be available through October 1, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the access code 11162643 to access the replay.
NEXGEL, through its Bionx Surgical division, offers a range of medical products including Biovance (human amniotic membrane allograft), Biovance 3L (tri-layer human amniotic membrane allograft), Interfyl (human connective tissue matrix), SilverSeal (antimicrobial hydrogel wound dressing), and an extensive ophthalmic portfolio of placental-derived ocular allografts (LUCENT, single layer, RADIANT, dual layer, and VIVID, triple layer). The company also provides healthcare, beauty, and over-the-counter (OTC) products, including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications.
The press release also notes that the call will include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which sections were adopted as part of the Private Securities Litigation Reform Act of 1995). These statements involve known and unknown risks, uncertainties, and other factors that may cause the company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements. For additional risks and uncertainties that could impact the company's forward-looking statements, please refer to the company's Annual Report on Form 10-K for the year ended December 31, 2025, including but not limited to the discussion under "Risk Factors" therein, which the company filed with the SEC.